UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

The New England journal of medicine, 2018-01, Vol.378 (4), p.331-344

2018

Link zum Volltext

Verfügbarkeit prüfen

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Blood, 2022-11, Vol.140 (Supplement 1), p.6838-6839

2022

Link zum Volltext

Verfügbarkeit prüfen

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Blood, 2022-11, Vol.140 (Supplement 1), p.1512-1513

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3662-TPS3662

2020

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

The New England journal of medicine, 2018-03, Vol.378 (9), p.878-878

2018

Link zum Volltext

Verfügbarkeit prüfen

Physician and Patient Perspectives on Relevant and Burdensome Symptoms of Non-Advanced Systemic Mastocytosis

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB222

2024

Link zum Volltext

Verfügbarkeit prüfen

Qualitative Research to Understand the Patient Experience in Non-Advanced Systemic Mastocytosis

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB53-AB53

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood, 2021-11, Vol.138 (Supplement 1), p.3636-3636

2021

Link zum Volltext

Verfügbarkeit prüfen

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Blood, 2021-11, Vol.138 (Supplement 1), p.3642-3642

2021

Link zum Volltext

Verfügbarkeit prüfen

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Haematologica (Roma), 2022-05, Vol.107 (5), p.1086-1094

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Journal of allergy and clinical immunology, 2024-02, Vol.153 (2), p.AB224

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacotherapy Prevention and Management of Nutritional Deficiencies Post Roux-en-Y Gastric Bypass

Obesity surgery, 2013-07, Vol.23 (7), p.992-1000

2013

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1647-1647

2018

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7532-7532

2019

Link zum Volltext

Verfügbarkeit prüfen

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1618-1618

2018

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7539-7539

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(5)
Science & Technology
(5)
Humans
(4)
Female
(3)
Hematology
(3)
Male
(3)
Adult
(2)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Bleomycin
(2)
Brentuximab Vedotin
(2)
Dacarbazine
(2)
Doxorubicin
(2)
General & Internal Medicine
(2)
Hodgkin Disease - Drug Therapy
(2)
Hodgkin Disease - Pathology
(2)
Hodgkin's Disease
(2)
Immunotherapy
(2)
Lymphoma
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(8)
Journal Of Allergy And Clinical Immunology
(3)
Journal Of Clinical Oncology
(3)
The New England Journal Of Medicine
(2)
Haematologica
(1)
Hematological Oncology
(1)
Obesity Surgery
(1)

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Physician and Patient Perspectives on Relevant and Burdensome Symptoms of Non-Advanced Systemic Mastocytosis

Qualitative Research to Understand the Patient Experience in Non-Advanced Systemic Mastocytosis

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Pharmacotherapy Prevention and Management of Nutritional Deficiencies Post Roux-en-Y Gastric Bypass

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Suchergebnisse filtern